KRAS

An let-7 KRAS rs712 polymorphism increases hepatocellular carcinoma risk

D. Xiong, Song, Y. P., Xiong, W., and Liang, Y. D., An let-7 KRAS rs712 polymorphism increases hepatocellular carcinoma risk, vol. 14, pp. 14050-14055, 2015.

KRAS, also known as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, acts as an intracellular signal transducer. The oncogenic KRAS mutation is an essential step in the development of many types of human cancers, including hepatocellular carcinoma. Here we aimed to investigate the relationship between KRAS rs712 polymorphisms and hepatocellular carcinoma susceptibility. Five-hundred-and-fourteen participants were enrolled in a case-control study (262 cases and 252 normal subjects).

Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai

Y. L. Wang, Dai, X., Li, Y. D., Cheng, R. X., Deng, B., Geng, X. X., and Zhang, H. J., Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai, vol. 14, pp. 14840-14846, 2015.

Phosphatidylinositol-3-OH kinase and RAS-activated signaling pathways play an important role in tumor formation. Abnormalities in relevant genes play essential roles in the occurrence and development of many human cancers. Studies of breast cancer have mainly focused on the women in western countries, but few studies have examined the frequency of mutations in PIK3CA, BRAF, and KRAS in Chinese breast cancer patients.

Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer

X. Huang, Yang, Y., Guo, Y., Cao, Z. L., Cui, Z. W., Hu, T. C., and Gao, L. B., Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer, vol. 14, pp. 16913-16920, 2015.

Breast cancer (BC) is a common malignancy affecting women, with increasing incidences of this disease in China every year. Recent studies have extensively investigated a single nucleotide polymorphism in the let-7 miRNA binding site of the 3'-untranslated region of KRAS mRNA. The aim of this study was to determine the genotype frequency of the KRAS rs712 polymorphism, and evaluate its effect on BC risk. This hospital-based case-control study comprised 228 patients with histologically confirmed BC and 251 healthy controls.

Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors

X. S. Li, Sun, J., and He, X. L., Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors, vol. 14, pp. 10752-10759, 2015.

We examined the expression of c-myc and mutations in the KRAS gene in ovarian mucinous tumors to explore the pathogenesis of these tumors and the feasibility of targeted gene therapy. Expression of c-myc protein and mutations in the KRAS gene in 24 cases of ovarian mucinous cystadenoma, 46 cases of ovarian borderline mucinous cystadenoma, and 46 cases of ovarian mucinous cystadenocarcinoma were detected using the immunohistochemistry PV-9000 2-step method and polymerase chain reaction-restriction fragment length polymorphism.

Subscribe to KRAS